Indian pharma stocks gain on US cancer drug shortage
BUZZ-Indian pharma stocks gain on US cancer drug shortage ** Indian pharma stocks .NIPHARM up 2.8% so far this week, set for their best weekly gain since May, if gains hold
** Stocks gain after media reports that the US FDA has reached out to Indian drugmakers for a critical cancer drug ifosfamide, which is in short supply due to manufacturing disruptions in the U.S.
** Sixteen of 20 stocks in sub-index record weekly gains, with Cipla CIPL.NS and Dr Reddy's REDY.NS up 7% each
** If current momentum holds, CIPL set for best week since July 2023 and REDY on track for best week since May
** YTD, pharma stocks jump 10.5% vs Nifty 50's .NSEI 7.5% drop
(Reporting by Kashish Tandon in Bengaluru)
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate